Vimarsana
Biggest News Aggregation in the World

Page 6 - Software Made Certain News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Software Made Certain. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Software Made Certain Today - Breaking & Trending Today

Cybeats Announces Participation in RSA Conference 2023 in San Francisco - Vimarsana News

Cybeats Announces Participation in RSA Conference 2023 in San Francisco

/PRNewswire/ - Cybeats Technologies Corp. ("Cybeats'' or the "Company")(CSE: CYBT) (OTCQB: CYBCF) is pleased to announce its attendance at the RSA Conference,...

Cybeats Addresses Recent '3CX' Cyberattack and Highlights Government Agencies' Support for SBOMs - Vimarsana News

Cybeats Addresses Recent '3CX' Cyberattack and Highlights Government Agencies' Support for SBOMs

/PRNewswire/ - Cybeats Technologies Corp. ("Cybeats'' or the "Company") (CSE: CYBT) (OTCQB: CYBCF) highlights the challenges faced by nations in securing their...

Cybeats Announces Private Placement and Closing of First Tranche - Vimarsana News

Cybeats Announces Private Placement and Closing of First Tranche

/PRNewswire/ - Cybeats Technologies Corp. ("Cybeats'' or the "Company")(CSE: CYBT) (OTCQB: CYBCF) is pleased to announce a non-brokered private placement up to...

Cybeats Announces Private Placement and Closing of First Tranche - Vimarsana News

Cybeats Announces Private Placement and Closing of First Tranche

TORONTO, April 6, 2023 /PRNewswire/ - Cybeats Technologies Corp.  is pleased to announce a non-brokered private placement up to 8,000,000 units of the Company at a price of $1.00 per Unit for... | June 20, 2023

FDA's Enhanced Role and SBOM Mandate Further Validates Market for Cybeats' SBOM Studio - Vimarsana News

FDA's Enhanced Role and SBOM Mandate Further Validates Market for Cybeats' SBOM Studio

/PRNewswire/ - Cybeats Technologies Corp. ("Cybeats'' or the "Company") (CSE: CYBT) is pleased to provide an update following the FDA's new Refuse-to-Accept...